Lenalidomide, melphalan, and prednisone, followed by lenalidomide maintenance, improves health-related quality of life in newly diagnosed multiple myeloma patients aged 65 years or older: results of a randomized phase III trial
oleh: Meletios A. Dimopoulos, Michel Delforge, Roman Hájek, Martin Kropff, Maria T. Petrucci, Philip Lewis, Annabel Nixon, Jingshan Zhang, Jay Mei, Antonio Palumbo
| Format: | Article |
|---|---|
| Diterbitkan: | Ferrata Storti Foundation 2013-05-01 |
Deskripsi
The MM-015 trial assessed the effect of lenalidomide-based therapy on health-related quality of life. Patients (n=459) with newly diagnosed multiple myeloma aged 65 years or over were randomized 1:1:1 to nine 4-week cycles of lenalidomide, melphalan, and prednisone, followed by lenalidomide maintenance; or lenalidomide, melphalan, and prednisone, or melphalan and prednisone, with no maintenance therapy. Patients completed health-related quality of life questionnaires at baseline, after every third treatment cycle, and at treatment end. Health-related quality of life improved in all treatment groups during induction therapy. Patients receiving lenalidomide maintenance had the most pronounced improvements, Global Health Status/Quality of Life (P